Sentences with phrase «early breast cancer patients»

Our team was the first to report that a single CTC detected in the blood of early breast cancer patients was associated with a higher risk of metastatic relapse (Pierga, Clin Cancer Res 2008).

Background In our institute, the first research program on disseminated tumor cells (DTC) detection in the bone marrow of early breast cancer patients was initiated in the late 90's; with about a thousand patients included, we constituted one of the largest cohort ever reported and contributed to the landmark report that established bone marrow DTC as a level - of - evidence 1 prognostic factor in early breast cancer (Braun, N Engl J Med 2005).

«Some early breast cancer patients benefit more from breast conservation than from mastectomy.»

Not exact matches

The trial has also included 10 HER -2-negative breast cancer patients, all of them in early stages of the disease.

The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumours in 50 % of patients suffering from early HER - 2 - negative breast cancer, the most common type of breast cancer.

Now a University of Colorado Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resisCancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resiscancer cells may have been pushed past an important tipping point that offers retinoic acid resistance.

According to Dr. Gass, «In an era where we see more early - staged breast cancer patients choosing mastectomy, no study has previously addressed breast specific sensuality, defined as the breast's role during intimacy.

The findings reveal that breast cancer patients who received local anesthetic had superior pain relief, spent less time in recovery rooms after surgery, and were discharged an hour earlier than patients who were put under general anesthesia.

An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1 % increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage.

Prior studies that examined the impact of cancer treatment decisions on employment showed that patients who received chemotherapy were most likely to experience longer disruptions in or loss of employment, but changes in breast cancer management in recent years have shifted recommendations away from chemotherapy for early stage breast cancer.

Dr. Sparano continued: «This is the first prospectively conducted clinical trial evaluating this assay — or any multigene expression assay for that matter — in which patients with early stage breast cancer were uniformly treated based on their assay results.

«Aspirin use does not improve outcomes for cancer patients, but may lower breast tissue density, allowing for earlier detection.»

The findings provide the highest level of evidence supporting expert - derived clinical practice guidelines which have recommended Oncotype DX in patients with early stage ER - positive breast cancer.

«The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk - stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medcancer, and indicate that the findings are generalizable to everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of MedCancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.

Since small, early - stage cancers are the most responsive to drug treatments, screening is an important aspect of follow - up care for breast cancer patients, and early detection is critical in tailoring appropriate and effective therapeutic interventions.

This shows promise for breast cancer patients as diagnosing and treating the breast cancer at early stages means there is a greater chance of preventing cancer cells spreading to other tissues, such as the lungs, brain and bone.

Furthermore, we demonstrate that perioperative anti-inflammatory treatment markedly reduces tumor outgrowth in this model, suggesting that similar approaches might substantially reduce early metastatic recurrence in breast cancer patients.

Relatively early metastatic recurrence after primary surgical resection is common in breast cancer patients.

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves — despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

Anti-inflammatory treatment reduced metastasis in the mice, and existing clinical data also suggest that perioperative anti-inflammatories reduced early metastatic recurrence in breast cancer patients.

«We have shown how a simple blood test has the potential to accurately predict which patients will relapse from breast cancer, much earlier than we can currently.

Intensity modulated radiotherapy (IMRT) gives better results than standard radiotherapy in patients with early breast cancer, according to results from a randomised trial presented today (Sunday) to the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO).

Appropriate patients with early stage breast cancer should not opt for less than this standard in care if properly educated,» Black continues.

In early - stage premenopausal breast cancer, for example, 10 - year survival rates were 68 % for African Americans versus 77 % for all other patients (mostly Caucasian) in the trials.

«This readily suggests that estrogen could be given to MS patients, except that high levels of estrogen are linked to breast and uterine cancers,» said Tiwari - Woodruff, who joined UCR earlier this year.

While the colorectal and breast cancer patients had no unusual CNVs, 7 % of those with early - onset testicular germ cell tumors — which are the vast majority of all testicular cancer cases — had a CNV that had developed de novo, that is not inherited directly from their parents but the result of a change to a sperm or egg cell.

In early clinical trials of these drugs, we noticed that in some breast cancer patients the tumors didn't just remain the same size — as would be expected with drugs that interfere with cell division — but began to recede, sometimes quite dramatically, said Goel.»

«This study demonstrates that Prosigna can reliably identify early stage breast cancer patients who have a low risk - of disease recurrence at 10 years, including a substantial proportion of patients with node - positive disease for whom the risk / benefit derived for adjuvant chemotherapy would be at best neutral,» said Dr. Alessandra Cesano, chief medical officer of NanoString Technologies.

«These results have driven us to update our treatment guidelines in Denmark to include testing with Prosigna as part of the workup of postmenopausal women with early stage HR - positive / Her -2 negative breast cancer, including patients with node - positive disease.»

Last month, a new study found that roughly 70 percent of women who carry cancer - predisposing mutations in the genes BRCA1 and BRCA2 (the main genes included in genetic tests for breast cancer patients) will develop breast cancer, often in early adulthood.

My translational research has focused on trying to find better ways to estimate recurrence risk in patients diagnosed with oestrogen - receptor positive early breast cancer, with the ultimate aim to better personalise our therapies for those patients who have the most to gain from them.

Research into the genes that control how breast cancer responds to treatment will help doctors provide patients with the most effective treatment for their tumour as early as possible, increasing their chance of survival.

Though trastuzumab and pertuzumab have increased response rates and improved outcomes in HER2 - positive breast cancer, 30 % to 40 % of early - stage patients treated in the neoadjuvant setting will have residual disease at the time of surgery.

The authors built a statistical simulation model to estimate the 25 - year incremental costs per quality - adjusted life - year (QALY) for Oncotype DX testing in order to evaluate the cost - effectiveness of GEP testing among patients with early - stage ER - positive / HER2 - negative breast cancer treated in community oncology practices.

The trial included 2,176 patients with early - stage HER2 - positive breast cancer and randomly assigned them to 9 - weeks trastuzumab or 12 - months trastuzumab.

Patients can be diagnosed with metastatic disease at the time of their breast cancer diagnosis or after a period of time has elapsed since their initial early breast cancer was treated.

Researchers found that shorter course of radiation therapy may provide lesser side effects for early stage breast cancer patients compared to the long - term treatments.

Analysis of microbial sequences in plasma cell - free DNA for early - onset breast cancer patients and healthy females — Yu - Feng Huang — BMC Medical Genomics

January 14, 2000 Protein predicts prognosis for breast cancer patients Low levels of E-cadherin, a protein that links cells together, appears to be the single most effective factor for predicting which patients with early breast cancer will need chemotherapy following surgery.

Low levels of a protein that helps link cells together appears to be the single most effective factor for predicting which patients with early breast cancer will need chemotherapy following surgery, report researchers from the University of Chicago Medical Center in the January 15, 2000 issue of Cancer Rescancer will need chemotherapy following surgery, report researchers from the University of Chicago Medical Center in the January 15, 2000 issue of Cancer ResCancer Research.

The researchers, studying women with node - negative breast cancer — the small, early tumors sought by mammography — found that by adding E-cadherin to other biomarkers that they have studied they are able to distinguish those patients with a 90 percent long - term survival from those whose survival is only 44 percent.

For example, the translational laboratory is providing support to a precision medicine - based clinical trial for patients with early - stage, triple - negative breast cancer.

Summary: Low levels of E-cadherin, a protein that links cells together, appears to be the single most effective factor for predicting which patients with early breast cancer will need chemotherapy following surgery.

In patients with metastatic breast cancer, our large multicenter study confirmed that CTC can be used as a prognostic marker and that dynamic early changes during chemotherapy are associated with the treatment outcome (Pierga, Ann Oncol 2012).

We know that far too many patients with curable cancers if they are caught at earlier stage, colon cancer, breast cancer, cervical cancer, these cancers are still detected late when they are less amenable to curative treatments.

A breast cancer vaccine developed at the School of Medicine is safe in patients with metastatic breast cancer, results of an early clinical trial indicate.

She tackles the big questions of why they evolved in the first place, how jet fuel ended up in breast milk, why they are arriving earlier and bigger in teen - aged girls, man boobs, and how breast cancer in men can help female breast cancer patients.

«In an ongoing multi-center study in heavily pretreated patients with breast cancer, CR011 is well tolerated and there is early evidence of activity.

Early Stage Breast Cancer Support Sisters Meet others diagnosed with breast cancer, share and learn coping techniques, facilitated by patient navigBreast Cancer Support Sisters Meet others diagnosed with breast cancer, share and learn coping techniques, facilitated by patient navigCancer Support Sisters Meet others diagnosed with breast cancer, share and learn coping techniques, facilitated by patient navigbreast cancer, share and learn coping techniques, facilitated by patient navigcancer, share and learn coping techniques, facilitated by patient navigators.

In 2014, researchers at the National Cancer Conference made the following statement: «Long term significant scalp alopecia (here lasting for up to 3.5 years following completion of chemotherapy) may affect 10 - 15 % of patients following docetaxel for EBC [early breast caCancer Conference made the following statement: «Long term significant scalp alopecia (here lasting for up to 3.5 years following completion of chemotherapy) may affect 10 - 15 % of patients following docetaxel for EBC [early breast cancercancer].